27656567|t|Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy
27656567|a|Visfatin is a new adipocytokine associated with both chronic periodontitis and type 2 diabetes mellitus independently. We aimed to estimate and compare the changes in the levels of visfatin in the Gingival Crevicular Fluid (GCF) of healthy subjects and in subjects with periodontitis with or without controlled Type 2 Diabetes Mellitus (T2DM) after administration of non-surgical periodontal therapy. Forty two subjects were equally divided into Group 1 (healthy), Group 2 (systemically healthy with chronic periodontitis), Group 3 (subjects with chronic periodontitis having controlled T2DM). Defined clinical parameters were recorded at baseline and at one month follow-up period. Visfatin was assessed using enzyme linked immunosorbent assay. One way ANOVA and Tukey's multiple post hoc procedures were used. Pearson's correlation coefficient was used for correlation. Significant increase in the visfatin levels was seen with the highest values observed in diabetes with periodontal disease. Visfatin responded to non-surgical periodontal therapy as observed by significant decrease in levels after one month but even at this period diabetics showed the highest levels. Visfatin levels are highest in individuals with both periodontal disease and diabetes even after periodontal therapy. Individuals with T2DM may be at higher risk of developing periodontal disease.
27656567	13	26	Periodontitis	T047	C0031099
27656567	31	55	Type 2 Diabetes Mellitus	T047	C0011860
27656567	73	83	Crevicular	T030	C0447436
27656567	84	92	Visfatin	T116,T126	C0068707
27656567	93	99	Levels	T080	C0441889
27656567	103	109	Health	T078	C0018684
27656567	117	124	Disease	T047	C0012634
27656567	125	131	Before	T079	C0332152
27656567	136	141	After	T079	C0687676
27656567	142	149	Initial	T079	C0205265
27656567	150	169	Periodontal Therapy	T061	C1882340
27656567	170	178	Visfatin	T116,T126	C0068707
27656567	188	201	adipocytokine	T116,T123	C1955907
27656567	202	217	associated with	T080	C0332281
27656567	223	244	chronic periodontitis	T047	C0266929
27656567	249	273	type 2 diabetes mellitus	T047	C0011860
27656567	274	287	independently	T033	C1299583
27656567	301	309	estimate	T081	C0750572
27656567	341	347	levels	T080	C0441889
27656567	351	359	visfatin	T116,T126	C0068707
27656567	367	392	Gingival Crevicular Fluid	T031	C0017564
27656567	394	397	GCF	T031	C0017564
27656567	402	418	healthy subjects	T098	C1708335
27656567	426	434	subjects	T096	C0681850
27656567	440	453	periodontitis	T047	C0031099
27656567	470	480	controlled	T169	C2587213
27656567	481	505	Type 2 Diabetes Mellitus	T047	C0011860
27656567	507	511	T2DM	T047	C0011860
27656567	519	533	administration	T061	C1533734
27656567	537	569	non-surgical periodontal therapy	T061	C2193643
27656567	581	589	subjects	T096	C0681850
27656567	603	610	divided	T169	C0332849
27656567	616	621	Group	T078	C0441833
27656567	625	632	healthy	T080	C3898900
27656567	635	640	Group	T078	C0441833
27656567	644	664	systemically healthy	T080	C3898900
27656567	670	691	chronic periodontitis	T047	C0266929
27656567	694	699	Group	T078	C0441833
27656567	703	711	subjects	T096	C0681850
27656567	717	738	chronic periodontitis	T047	C0266929
27656567	746	756	controlled	T169	C2587213
27656567	757	761	T2DM	T047	C0011860
27656567	772	780	clinical	T080	C0205210
27656567	781	791	parameters	T033	C0449381
27656567	797	805	recorded	T169	C0205245
27656567	809	817	baseline	T081	C1442488
27656567	829	834	month	T079	C0439231
27656567	835	844	follow-up	T058	C1522577
27656567	845	851	period	T079	C1948053
27656567	853	861	Visfatin	T116,T126	C0068707
27656567	866	874	assessed	T052	C1516048
27656567	881	914	enzyme linked immunosorbent assay	T059	C0014441
27656567	916	929	One way ANOVA	T081	C1709320
27656567	934	959	Tukey's multiple post hoc	T081	C0392762
27656567	960	970	procedures	T169	C2700391
27656567	982	1015	Pearson's correlation coefficient	T081	C0871052
27656567	1029	1040	correlation	T080	C1707520
27656567	1042	1053	Significant	T078	C0750502
27656567	1054	1062	increase	T169	C0442805
27656567	1070	1078	visfatin	T116,T126	C0068707
27656567	1079	1085	levels	T080	C0441889
27656567	1104	1111	highest	T080	C1522410
27656567	1112	1118	values	T081	C1522609
27656567	1119	1127	observed	T169	C1441672
27656567	1131	1139	diabetes	T047	C0011847
27656567	1145	1164	periodontal disease	T047	C0031090
27656567	1166	1174	Visfatin	T116,T126	C0068707
27656567	1188	1220	non-surgical periodontal therapy	T061	C2193643
27656567	1224	1232	observed	T169	C1441672
27656567	1236	1247	significant	T078	C0750502
27656567	1248	1256	decrease	T081	C0547047
27656567	1260	1266	levels	T080	C0441889
27656567	1277	1282	month	T079	C0439231
27656567	1300	1306	period	T079	C1948053
27656567	1307	1316	diabetics	T033	C0241863
27656567	1328	1335	highest	T080	C1522410
27656567	1336	1342	levels	T080	C0441889
27656567	1344	1352	Visfatin	T116,T126	C0068707
27656567	1353	1359	levels	T080	C0441889
27656567	1364	1371	highest	T080	C1522410
27656567	1375	1386	individuals	T098	C0027361
27656567	1397	1416	periodontal disease	T047	C0031090
27656567	1421	1429	diabetes	T047	C0011847
27656567	1441	1460	periodontal therapy	T061	C1882340
27656567	1462	1473	Individuals	T098	C0027361
27656567	1479	1483	T2DM	T047	C0011860
27656567	1491	1505	at higher risk	T033	C3843761
27656567	1520	1539	periodontal disease	T047	C0031090